SCHEMBL410508

SCHEMBL410508

CCOc1cnc(C(=O)OC)nc1-c1ccc(Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.43
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 3/20 0.40
TP53 P04637 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
GABRA5 P31644 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411484 0.87 KMO (0.47) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL440973 0.85 MRGPRX4 (0.41) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL411006 0.84 CNR1 (0.51) CNR1SLC6A3
SCHEMBL411014 0.80 MAPT (0.44) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL444452 0.79 RORC (0.39) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL412129 0.79 RORC (0.39) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL28988563 0.75 LMNA (0.45) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25551995 0.74 ALDH1A1 (0.60) MAPTSMN1; SMN2NPC1ALDH1A1GABRA5
SCHEMBL411960 0.73 SLC6A3 (0.41) MAPTKDM4EPKMKMT2AMEN1
SCHEMBL30881476 0.72 MAP2K4 (0.52) MAPTSMN1; SMN2NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090599-B2 Heteroarylmethyl amides HOFFMANN-LA ROCHE INC. (US) 2015-07-28 US disclosed
US-20140194436-A1 HETEROARYLMETHYL AMIDES HOFFMANN-LA ROCHE INC. (US) 2014-07-10 US disclosed
US-8729105-B2 Heteroarylmethyl amides HOFFMANN LA-ROCHE INC. (US) 2014-05-20 US disclosed
US-20120065212-A1 HETEROARYLMETHYL AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194436-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR GRM5 3048/4885MAPT 4619/4885SMN1; SMN2 4004/4885
US-20120065212-A1 HETEROARYLMETHYL AMIDES APOB, LDLR, HMGCR GRM5 3048/4885MAPT 4619/4885SMN1; SMN2 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.